2005
Electrocardiographic Changes in Children and Adolescents Treated With Ziprasidone: A Prospective Study
BLAIR J, SCAHILL L, STATE M, MARTIN A. Electrocardiographic Changes in Children and Adolescents Treated With Ziprasidone: A Prospective Study. Journal Of The American Academy Of Child & Adolescent Psychiatry 2005, 44: 73-79. PMID: 15608546, DOI: 10.1097/01.chi.0000145372.61239.bb.Peer-Reviewed Original ResearchConceptsQTc intervalClose electrocardiographic monitoringMean QTc prolongationQTc-prolonging agentsOpen-label trialLonger QTc intervalsCurrent treatment standardsQRS complex widthZiprasidone dosePediatric outpatientsQTc prolongationElectrocardiographic changesElectrocardiographic monitoringProspective studyMean ageSafety profilePeak QTcHeart rateHigh dosesZiprasidoneTreatment standardsDoseDosesPreliminary findingsProlongation
2003
Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study
Martin A, Koenig K, Anderson GM, Scahill L. Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study. Journal Of Autism And Developmental Disorders 2003, 33: 77-85. PMID: 12708582, DOI: 10.1023/a:1022234605695.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderSelective serotonin reuptake inhibitor responseOpen-label studyOpen-label trialLow-dose fluvoxamineDevelopmental disordersPremature discontinuationClinical responseFluvoxamine treatmentPartial respondersMean ageSerotonin levelsSelect childrenPubertal statusInhibitor responseBehavioral activationFluvoxamineChildrenFurther investigationDisordersTreatmentGender differencesAdolescentsSubjectsTolerability
2000
Research Units on Pediatric Psychopharmacology (Rupp) Autism Network Background and Rationale for an Initial Controlled Study of Risperidone
McDougle C, Scahill L, McCracken J, Aman M, Tierney E, Arnold L, Freeman B, Martin A, McGough J, Cronin P, Posey D, Riddle M, Ritz L, Swiezy N, Vitiello B, Volkmar F, Votolato N, Walson P. Research Units on Pediatric Psychopharmacology (Rupp) Autism Network Background and Rationale for an Initial Controlled Study of Risperidone. Child And Adolescent Psychiatric Clinics Of North America 2000, 9: 201-224. PMID: 10674197, DOI: 10.1016/s1056-4993(18)30142-1.Peer-Reviewed Original ResearchConceptsOpen-label trialDA neuronal systemsSafety of risperidoneStudy of RisperidonePlacebo-controlled studyUse of risperidoneExtrapyramidal side effectsTarget of pharmacotherapyTreatment of childrenImpaired social behaviorLong-term effectivenessPreclinical evidenceReceptor blockadeTypical antipsychoticsControlled StudyFirst drugPathophysiology of autismLower riskShort-term benefitsSide effectsRisperidonePotent effectsSymptoms of autismNeuronal systemsEnhanced efficacy
1999
Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder
Martin A, Koenig K, Scahill L, Bregman J. Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder. Journal Of Child And Adolescent Psychopharmacology 1999, 9: 99-107. PMID: 10461820, DOI: 10.1089/cap.1999.9.99.Peer-Reviewed Original ResearchConceptsClinical Global Impression ScaleTreatment of childrenSide effectsAutistic disorderOpen-label trialShort-term safetyWeeks of treatmentGlobal Impression ScaleGlobal improvement itemSignificant side effectsSerious side effectsDSM-IV criteriaFurther dose increasesLack of responseMean ageImpression ScalePossible seizuresMale subjectsWeight gainBehavioral activationFourth weekQuetiapine fumarateDose increaseClinical populationsWeeks